🔥🐔 BizChicken 🐔🔥

Learn About the Corporations Around You

Sign Up Today!

Sign up for BizChicken and discover more about the corporations around you.

Mersana Therapeutics, Inc.

Mersana Therapeutics, Inc. logo
Market Cap: Low
Employees: Low

XMT-1592

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on developing antibody drug conjugates (ADC) for treating cancer patients with unmet needs. It specializes in ADC products like XMT-1592 and has strategic partnerships for the advancement of its innovative therapeutics.

Tags: ADC, XMT-1592, biopharmaceutical, cancer treatment, clinical trials, partnerships

Symbol: MRSN

Recent Price: $1.42

Industry: Biotechnology

CEO: Dr. Martin H. Huber M.D.

Sector: Healthcare

Employees: 123

Address: 840 Memorial Drive, Cambridge, MA 02139

Phone: 617 498 0020

Leadership

  • David Mott, Chairman of the Board
  • Lawrence Alleva, Retired Partner, PriceWaterhouseCoopers
  • Willard H. Dere, MD, Professor Emeritus of Internal Medicine, University of Utah
  • Allene M. Diaz, Independent Commercial Strategy and Portfolio Management Consultant, AMD Consulting
  • Andrew Hack MD, PhD, Managing Director, Bain Capital Life Sciences
  • Kristen M. Hege, MD, Retired Senior Vice President, Early Clinical Development, Hematology/Oncology & Cell Therapy, Bristol Myers Squibb Company
  • Anna Protopapas, Chair of the board of directors of Nuvalent
  • Martin Huber, MD, President and Chief Executive Officer

Last updated: 2024-12-31